Class information for:
Level 1: ACROMEGALY//PEGVISOMANT//GROWTH HORMONE RECEPTOR ANTAGONIST

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
2070 2300 35.1 76%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
385 16364 PITUITARY ADENOMA//CRANIOPHARYNGIOMA//ACROMEGALY

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ACROMEGALY Author keyword 501 49% 32% 736
2 PEGVISOMANT Author keyword 119 82% 3% 69
3 GROWTH HORMONE RECEPTOR ANTAGONIST Author keyword 35 89% 1% 16
4 SOMATOSTATIN ANALOGS Author keyword 29 32% 3% 73
5 LANREOTIDE Author keyword 24 35% 2% 57
6 ACROMEGALIC CARDIOMYOPATHY Author keyword 20 100% 0% 9
7 MOL CLIN ENDOCRINOL ONCOL Address 19 19% 4% 90
8 PITUITARY Journal 18 17% 4% 99
9 ACROMEGALY TREATMENT Author keyword 11 100% 0% 6
10 SOMATOSTATIN ANALOGUES Author keyword 9 19% 2% 41

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 ACROMEGALY 501 49% 32% 736 Search ACROMEGALY Search ACROMEGALY
2 PEGVISOMANT 119 82% 3% 69 Search PEGVISOMANT Search PEGVISOMANT
3 GROWTH HORMONE RECEPTOR ANTAGONIST 35 89% 1% 16 Search GROWTH+HORMONE+RECEPTOR+ANTAGONIST Search GROWTH+HORMONE+RECEPTOR+ANTAGONIST
4 SOMATOSTATIN ANALOGS 29 32% 3% 73 Search SOMATOSTATIN+ANALOGS Search SOMATOSTATIN+ANALOGS
5 LANREOTIDE 24 35% 2% 57 Search LANREOTIDE Search LANREOTIDE
6 ACROMEGALIC CARDIOMYOPATHY 20 100% 0% 9 Search ACROMEGALIC+CARDIOMYOPATHY Search ACROMEGALIC+CARDIOMYOPATHY
7 ACROMEGALY TREATMENT 11 100% 0% 6 Search ACROMEGALY+TREATMENT Search ACROMEGALY+TREATMENT
8 SOMATOSTATIN ANALOGUES 9 19% 2% 41 Search SOMATOSTATIN+ANALOGUES Search SOMATOSTATIN+ANALOGUES
9 PASIREOTIDE 8 29% 1% 22 Search PASIREOTIDE Search PASIREOTIDE
10 BIM 23A760 6 80% 0% 4 Search BIM+23A760 Search BIM+23A760

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 SLOW RELEASE LANREOTIDE 189 87% 4% 93
2 HORMONE RECEPTOR ANTAGONIST 174 78% 5% 113
3 SANDOSTATIN LAR 107 90% 2% 46
4 SECRETING PITUITARY ADENOMAS 102 49% 7% 151
5 TUMOR SHRINKAGE 98 79% 3% 62
6 PRIMARY MEDICAL THERAPY 77 75% 2% 56
7 PEGVISOMANT 72 67% 3% 65
8 OCTREOTIDE LAR 67 66% 3% 63
9 ACROMEGALIC PATIENTS 64 44% 5% 112
10 RECEPTOR ANTAGONIST PEGVISOMANT 62 75% 2% 45

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PITUITARY 18 17% 4% 99

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
EXPERT CONSENSUS DOCUMENT A consensus on the medical treatment of acromegaly 2014 26 73 88%
Medical progress: Acromegaly 2006 360 89 66%
Systemic complications of acromegaly: Epidemiology, pathogenesis, and management 2004 454 383 49%
Resistance to Somatostatin Analogs in Acromegaly 2011 47 177 77%
Update on prognostic factors in acromegaly: Is a risk score possible? 2015 2 88 52%
A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly 2008 72 58 91%
Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis 2015 1 38 79%
Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management 2015 1 98 78%
Treatment of acromegaly in the era of personalized and predictive medicine 2015 1 83 77%
Place of Preoperative Treatment of Acromegaly with Somatostatin Analog on Surgical Outcome: A Systematic Review and Meta-Analysis 2013 12 44 84%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 MOL CLIN ENDOCRINOL ONCOL 19 19% 3.9% 90
2 ENDOCRINOL METABNEUROENDOCRINE UNIT 7 64% 0.3% 7
3 NORTHWEST PITUITARY 6 48% 0.4% 10
4 ALLEGHENY NEUROENDOCRINOL 3 100% 0.1% 3
5 ENDOCRINOL CHUS 3 100% 0.1% 3
6 INVEST BIOMED ENFERMEDADES RARAS CIBER ER UNI 3 100% 0.1% 3
7 PHARMACOKINET METAB SERV 3 100% 0.1% 3
8 TEACHING HOSP BOGENHAUSEN 3 100% 0.1% 3
9 ENDOCRINE MED SCI 3 45% 0.2% 5
10 EXPT ENDOCRINOL UNIT 3 45% 0.2% 5

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000226252 PITUITARY INCIDENTALOMA//RADIATION OPTIC NEUROPATHY//LARS LEKSELL GAMMA KNIFE
2 0.0000127772 GONADOTROPH ADENOMA//TSH SECRETING ADENOMA//PLURIHORMONALITY
3 0.0000092945 PITUITARY CARCINOMA//PTTG//PITUITARY TUMOR TRANSFORMING GENE 1
4 0.0000092121 GROWTH HORMONE DEFICIENCY//ADULT GH DEFICIENCY//ADULT GROWTH HORMONE DEFICIENCY
5 0.0000083665 MACROPROLACTIN//PROLACTINOMA//HYPERPROLACTINEMIA
6 0.0000082343 SOMATOSTATIN//SOMATOSTATIN RECEPTORS//SOMATOSTATIN RECEPTOR
7 0.0000081279 SALFORD ROYAL HOSP UNIV TRUST//MED 0613B//MED HUMAN LIFE SCI
8 0.0000078639 REFRACTORY DIARRHEA//MCKITTRICK WHEELOCK SYNDROME//DUMPING SYNDROME
9 0.0000052718 20K HGH//22K HGH//GH ABUSE
10 0.0000051486 TALL GIRLS//TALL STATURE//CONSTITUTIONAL TALL STATURE